At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Fludarabine +2 moredrug
Likely dose
Fludarabine 30 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sequential Myeloablative Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease
In Brief
A Phase 2 clinical trial evaluating Fludarabine, Busulfan, and 1 other intervention for Non-Hodgkin's Lymphoma and Hodgkins Disease. Completed, enrolled 30 participants across 6 sites.
Detailed Summary
The sequential combination of myeloablative therapy and autologous stem cell transplantation (APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post SCT adoptive cellular immunotherapy will be well tolerated in patients with refractory or recurrent non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma, Hodgkins Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2003
First PostedDec 2008
Primary CompletionOct 2014
Study CompletionOct 2014
TodayJul 2026
First PostedDec 4, 2008
Enrollment StartJun 1, 2003
Primary CompletionOct 1, 2014
Study CompletionOct 22, 2014
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 17.6 years ago
Interventions
Fludarabinedrug
Fludarabine 30 mg/m2 x 5 days
Busulfandrug
Busulfan 3.2 mg/kg/day x 2 days
Anti-Thymocyte Globulindrug
Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days